BECN1 and osteosarcoma: Luteolin can be used as an adjuvant in osteosarcoma therapy [39] Luteolin (100–200 μM) potentiated autophagy induced by doxorubicin in human osteosarcoma U2OS cells via up-regulating beclin1.